Click on headlines below to download research

Value-add specialist
Grand City Properties | 25/04/2017

Grand City Properties (GCP) is a specialist residential real estate company investing in underperforming assets in major German urban centres. Its €4.9bn…

Becoming an increasingly prominent player
Medigene | 24/04/2017

Medigene is well funded (FY16 cash €52.6m) to advance both its DC vaccine programmes and TCR programme. We expect a number of important milestones…

Rapid start to DBAG Fund VII’s investment period
Deutsche Beteiligungs | 21/04/2017

Deutsche Beteiligungs (DBAG) has continued into FY17 the strong pace of portfolio activity achieved in the previous two financial years, with c €63m…

Termination of coverage
Epigenomics | 13/04/2017

Edison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or estimates for…

Termination of coverage
Ifa Systems | 11/04/2017

Edison Investment Research is terminating coverage on Ifa Systems (IS8). Please note you should no longer rely on any previous research or estimates for…

Time to capitalise on its core focus - trauma
aap Implantate | 06/04/2017

aap Implantate announced that it successfully completed its transformation to a pure trauma player in 2016. The company reported challenging FY16 results…

Consolidation in FY17, acceleration in FY18
GFT | 31/03/2017

While GFT reported FY16 revenues and EBITDA slightly ahead of our forecasts, the shares fell in response to unexpectedly weak FY17 guidance and higher…

A streamlined focus moving forward
4SC | 30/03/2017

2016 was an important year for 4SC as it launched its potentially pivotal Phase II study with resminostat, an epigenetic cancer drug, in CTCL. In addition,…

Positive data in high-risk patients
Paion | 27/03/2017

Paion has taken an important step towards its goal of US approval for its ultra-fast-acting sedative, remimazolam with the announcement of positive top…

Xadago receives FDA approval in PD
Newron Pharmaceuticals | 22/03/2017

Newron and its partners Zambon and US WorldMeds have announced that the FDA has approved Xadago (safinamide) for Parkinson’s disease (PD) patients…

On track to file in US and Japan by mid-2018
Paion | 20/03/2017

Paion has successfully accelerated recruitment in the confirmatory pivotal bronchoscopy study of its ultra-fast-acting sedative remimazolam in procedural…

Termination of coverage
Evotec | 19/03/2017

Edison Investment Research is terminating coverage on Evotec (EVT). Please note you should no longer rely on any previous research or estimates for this…

Hitting form
Borussia Dortmund | 16/03/2017

Although in transition after high-profile player departures, Borussia Dortmund (BVB) continues to compete well on all fronts. Its financial performance…

Headroom improves
Evolva | 16/03/2017

Evolva has secured equity financing of up to CHF30m. This is a fully flexible arrangement with relatively good terms, which if drawn down in full would…

Marching into 2017
Newron Pharmaceuticals | 13/03/2017

We anticipate that the sales and pipeline progression made by Newron in 2016 will be cemented further in 2017/18. A critical catalyst remains the US Xadago…

Upgraded on healthy cash flows post acquisition
Evotec | 07/03/2017

Evotec ended 2016 with the landmark deal with Celgene for Evotec’s induced pluripotent stem cell (iPSC) platform, bringing in a $45m upfront payment.…

Strong rebound for established specialist
BB Biotech | 27/02/2017

BB Biotech (BION) is a long-established investor in biotech innovation, offering access to a concentrated portfolio of c 30 companies covering a range…

Another strong year expected
SinnerSchrader | 02/02/2017

The Q1 results point to another year of solid revenue growth and further EBITA margin expansion. While SinnerSchrader’s P/E rating has caught up…

Increased scale offers greater opportunities
Deutsche Beteiligungs | 31/01/2017

FY16 proved to be a significant year for Deutsche Beteiligungs (DBAG). In addition to generating strong NAV returns and maintaining an elevated level of…

Termination of coverage
PSI Group | 23/01/2017

Edison Investment Research is terminating coverage on PSI (PSAN). Please note you should no longer rely on any previous research or estimates for this…

A cloudier picture
Evolva | 16/01/2017

The much-awaited stevia update has confirmed that EverSweet is still on track to be launched in 2018, and there is a new production plan. That said, talks…

Continuing to take steps to focus on core
Medigene | 21/12/2016

Medigene has announced that it has granted an exclusive worldwide licence for the development and commercialisation of its preclinical-stage adeno-associated…

First patient enrolled in pivotal RESMAIN study
4SC | 19/12/2016

4SC has announced the enrolment of the first patient in its RESMAIN study. This is a pivotal study to evaluate resminostat (RES), an epigenetic cancer…

Termination of coverage
Stratec Biomedical | 13/12/2016

Edison Investment Research is terminating coverage on Stratec Biomedical (SBS). Please note you should no longer rely on any previous research or estimates…

Dividend increased 67%
SinnerSchrader | 28/11/2016

SinnerSchrader (SZZ) expects another year of double-digit revenue growth and margin improvement in FY17, underpinned by the Audi win. This confidence is…